A novel and accurate predictor of survival for patients with hepatocellular carcinoma after surgical resection: the neutrophil to lymphocyte ratio (NLR) combined with the aspartate aminotransferase/platelet count ratio index (APRI)

Fei Ji, Yao Liang, Shun-Jun Fu, Zhi-Yong Guo, Man Shu, Shun-Li Shen, Shao-Qiang Li, Bao-Gang Peng, Li-Jian Liang and Yun-Peng Hua

Abstract

Background: The occurrence and development of hepatocellular carcinoma (HCC) depends largely on such non-tumor factors as inflammatory condition, immune state, viral infection and liver fibrosis. Various inflammation-based prognostic scores have been associated with survival in patients with HCC, such as the neutrophil/lymphocyte ratio (NLR), the platelet/lymphocyte ratio (PLR) and the prognostic nutritional index (PNI). The aspartate aminotransferase/platelet count ratio index (APRI) is thought to be a biomarker of liver fibrosis and cirrhosis. This study aims to evaluate the ability of these indices to predict survival in HCC patients after curative hepatectomy, and probe the increased prognostic accuracy of APRI combined with established inflammation-based prognostic scores.

Methods: Data were collected retrospectively from 321 patients who underwent curative resection for HCC. Preoperative NLR, PLR, PNI, APRI and clinico-pathological variables were analyzed. Univariate and multivariate analyses were performed to identify the predictive value of the above factors for disease-free survival (DFS) and overall survival (OS).

Results: Univariate analysis showed that NLR, PLR, PNI and APRI were significantly associated with DFS and OS in HCC patients with curative resection. Multivariate analysis showed that NLR and APRI were superior to PLR and PNI, and both were independently correlated with DFS and OS. Preoperative NLR >2 or APRI >1.68 predicted poor prognosis of patients with HCC after hepatectomy. Furthermore, the predictive range of NLR combined with APRI was more sensitive than that of either measure alone.

Conclusions: Preoperative NLR and APRI are independent predictors of DFS and OS in patients with HCC after surgical resection. Higher levels of NLR or APRI predict poorer outcomes in HCC patients. Intriguingly, combining NLR and APRI increases the prognostic accuracy of testing.

Keywords: Neutrophil to lymphocyte ratio, Aspartate aminotransferase/platelet count ratio index, Hepatocellular carcinoma, Prognosis, Biomarkers
Background
Hepatocellular cancer (HCC) is one of the most common and most aggressive malignancies, the third leading cause of cancer-related deaths worldwide [1, 2]. Unlike other solid malignancies, most HCCs result from chronic liver disease [3], and the outcome of HCC depends in part on impaired liver function secondary to the above pathogenic condition, rather than solely to the tumor burden. Though Tumor Node Metastasis (TNM) staging system is an effective independent prognostic factor for HCC, its prognostic value is limited and lagging. A reliable prognostic index is therefore needed in routine clinical practice.

In addition to the intrinsic properties of cancer cells, host-related factors are increasingly recognized to influence the progression of tumors [4, 5]. For example, a systemic inflammatory response can impact tumor development through the inhibition of apoptosis, promotion of angiogenesis, and damage to the DNA. The pathogenesis of HCC is based on inflammation often caused by hepatotropic virus infection or ethanol consumption. Moreover, 70-90 % of HCCs are a result of cirrhosis [6, 7]. In recent studies, inflammation-based prognostic scores, such as the combination of albumin and lymphocyte counts used in the prognostic nutritional index (PNI) [5, 8], the combination of neutrophil and lymphocyte counts in the neutrophil/lymphocyte ratio (NLR) [9–11], and the combination of platelet (PLT) and lymphocyte counts in the PLT/lymphocyte ratio (PLR) [12], have proved valuable in HCC prediction. In addition, recent studies [13–15] suggest that a simple and accurate biochemical marker of liver fibrosis and cirrhosis, i.e., the aspartate aminotransferase (AST)/PLT count ratio index (APRI), may be 1) an indicator of post-operative prognosis in early stage hepatitis B (HBV)-related HCC patients, or 2) a marker of HCC risk in HBV patients.

However, few studies have compared the prognostic value of these indices to predict tumor recurrence and survival after curative resection for HCC. Indeed, the combination of APRI and inflammation-based prognostic scores may increase the accuracy of prognosis prediction in patients who have undergone radical hepatectomy for HCC.

Methods
Study population
A total of 321 histologically proven HCC patients with hepatic resection from our hospital were recruited between 2006 and 2009. Written informed consent was obtained from all patients and this study complied with the standards of the Helsinki Declaration and current ethical guidelines and was approved by the Institutional Ethical Board of First Affiliated Hospital of Sun Yat-sen University. Routine assessment was performed within seven days before surgery, including a complete physical examination, hematologic and biochemistry profiles, chest X-ray, abdominal ultrasound and computed tomography (CT) or magnetic resonance imaging (MRI).

Eligibility criteria included: the International Union Against Cancer (seventh edition) TNM stage I, II, IIIA or IIIB [16]; Child-Pugh class A hepatic function; age 18-80 years; and written informed consent. Exclusion criteria included: TNM stage IIIC, IVA or IVB; existing second malignancy or history of second malignancy within the past five years; hematologic disorders; peri-operative dysfunction of vital organs; or percutaneous ablation, transcatheter arterial chemoembolization (TACE), chemotherapy or radiotherapy within one month after surgery.

Blood samples were obtained before initial treatment to determine albumin, AST, alanine aminotransferase (ALT), total bilirubin (TBIL), white blood cell count, neutrophil count, lymphocyte count, platelet (PLT) count, prothrombin time and the a-fetoprotein (AFP) level. NLR, PLR, PNI and APRI were calculated using the following formulas:

\[
\text{NLR} = \frac{\text{Neutrophil count}}{\text{Lymphocyte count}}; \\
\text{PLR} = \frac{\text{PLT count}}{\text{Lymphocyte count}}; \\
\text{PNI} = 10 \times \frac{\text{serum albumin (g/dl)}}{0.005 \times \text{total lymphocyte count (per mm3)}}; \text{and} \\
\text{APRI} = \frac{\text{AST(}IU/L\text{)/upper limit normal}}{\text{PLT}(\times 10^9/L)} \times 100.
\]

Treatment and follow-up
Hepatectomy was defined as radical when there was no evidence of distant metastases and tumor clearance was complete both macroscopically and histologically. All patients were regularly followed up according to institutional practice, including liver ultrasound, chest X-ray and serum AFP every three months, and contrast CT every 6 months. Tumor relapse was defined by clinical, radiological and/or pathological diagnosis. After diagnosing recurrence, salvage treatments were selected, including re-operation, percutaneous ablation or TACE.

Statistical analysis
Statistical analysis was performed using SPSS for Windows version 20.0 (SPSS, Chicago, IL, USA). Receiver operating characteristic (ROC) curve analysis was performed to select the most appropriate cut-off values for NLR, PLR, PNI and APRI to stratify patients at a high risk of death. The χ2 test was used to compare categorical variables. Disease-free survival (DFS) was calculated from the date of surgery to the date of recurrence, and overall survival (OS) from the date of surgery to the date
of HCC-associated death. The Kaplan-Meier method was used to estimate the survival rates for different groups, and the equivalences of the survival curves were tested by log-rank statistics. The Cox proportional hazards model was used for univariate and multivariate survival analyses. \( P < 0.05 \) was considered statistically significant.

### Results

#### Patient and tumor characteristics

The study included 285 male patients (88.8 \%) and 36 female patients (11.2 \%). The mean age was 51 years (range 21–79 years). A total of 235 patients (73.2 \%) developed recurrence and 202 patients (62.9 \%) died during follow up. Hepatitis B surface antigen (HBsAg) was positive in 281 patients (87.5 \%) and cirrhosis in 253 (78.8 \%) patients. Increased AFP levels (≥200 \( \mu \)g/L) were observed in 182 patients (56.7 \%), and 95 patients (29.6 \%) had multiple tumor masses. Mean tumor size was 87.6 mm (range 10–300 mm) in greatest diameter, and 210 (65.4 \%) patients had tumors ≥50 mm in diameter. According to the Edmonson–Steiner stage of tumor differentiation, 248 (77.3 \%) patients were in stages I–II and 73 (22.7 \%) patients were in stages III–IV. Likewise, according to TNM classification, 185 patients were in TNM stage I and 137 patients in TNM stage II–III (Table 1).

#### Determination of cut-off value

Using 5-year overall survival rate as an endpoint, stratification of each prognostic index was calculated by ROC curve analyses, according to the maximum joint sensitivity and specificity values based on the peak and cut-off points. Our results indicated that the optimal cut-off values for NLR, PLR, PNI and APRI were 2, 115, 45 and 1.68, respectively (Fig. 1).

#### Independent prognostic factors for HCC

To further identify the risk factors linked to postoperative DFS and OS, NLR, PLR, PNI, APRI and 17 clinico-pathologic factors were evaluated by univariate analysis and the Cox regression model. Univariate analysis showed that the significant prognostic factors for DFS in HCC patients were HBsAg, AFP, TNM stage, tumor number, portal vein tumor thrombus (PVTT), tumor differentiation, intraoperative blood loss, NLR, PLR, PNI and APRI (all \( P < 0.05 \)). Similarly, the significant factors for OS for those with HCC were gender, AFP, ALT, TNM stage, tumor number, PVTT, tumor differentiation, resection margin, intraoperative blood loss, NLR, PLR, PNI and APRI (all \( P < 0.05 \)). After multivariate analysis, we found that AFP, TNM, PVTT, NLR and APRI were significant independent predictors of DFS (all \( P < 0.05 \)), while TNM, PVTT, NLR, PLR and APRI were significant independent predictors of OS (all \( P < 0.05 \)) (Tables 1 and 2).

#### Correlation between preoperative NLR or APRI and 17 clinico-pathologic characteristics in HCC

In order to further understand the prognostic value of preoperative NLR or APRI on HCC patients after resection, the relationships between NLR or APRI and 17 clinico-pathologic characteristics were analyzed. A NLR > 2 was more frequently observed in patients with high serum AFP levels (\( P = 0.015 \)), with tumor size > 5 cm (\( P < 0.001 \)), those with PVTT (\( P = 0.002 \)), with recurrence (\( P = 0.005 \)), with PNI ≤ 45 (\( P < 0.001 \)) and with PLR > 115 (\( P < 0.001 \)). Likewise, an APRI > 1.68 was associated with HBsAg (\( P = 0.015 \)), a low PLT level (\( P < 0.001 \)), a high ALT level (\( P < 0.001 \)), TBIL (\( P = 0.003 \)), cirrhosis (\( P = 0.001 \)), PVTT (\( P < 0.001 \)), recurrence (\( P = 0.001 \)) and PNI ≤ 45 (\( P < 0.001 \)) (Table 3).

#### Overall and disease free survival rates according to NLR or APRI

To determine the ability of NLR and APRI to predict OS and DFS, the 321 HCC patients were divided into two groups according to their NLR profiles: the NLR ≤ 2 group (\( n = 153 \)) and the NLR > 2 group (\( n = 168 \)). Using the Kaplan-Meier method to analyze patient survival, we found that the 1-, 3- and 5-year DFS rates of the NLR ≤ 2 group were markedly higher than those of the NLR > 2 group (53.6 \%, 39.2 \% and 34.6 \% vs 36.9 \%, 23.2 \% and 20.6 \%, respectively, \( P < 0.001 \)) (Fig. 2a), while the 1-, 3- and 5-year OS rates of the NLR ≤ 2 group were also significantly higher than those of the NLR > 2 group (79.7 \%, 58.8 \% and 49.6 \% vs 63.1 \%, 35.1 \% and 29.7 \%, respectively, \( P < 0.001 \)) (Fig. 2b). Our findings therefore indicated that high NLR levels were correlated with a low survival rate in patients with HCC.

Likewise, the HCC patients were divided into two groups according to their APRI profiles: the APRI ≤ 1.68 group (\( n = 108 \)) and the APRI > 1.68 group (\( n = 213 \)). The 1-, 3- and 5-year DFS rates of the APRI ≤ 1.68 group were markedly higher than those of the APRI > 1.68 group (57.4 \%, 40.7 \% and 37.8 \% vs 38.5 \%, 25.8 \% and 21.9 \%, respectively, \( P < 0.001 \)) (Fig. 3a). Also, the 1-, 3- and 5-year OS rates of the APRI ≤ 1.68 group were significantly higher than those of the APRI > 1.68 group (83.3 \%, 59.3 \% and 51.8 \% vs 64.8 \%, 39.9 \% and 32.8 \%, respectively, \( P < 0.001 \)) (Fig. 3b). A high APRI level therefore implied poor DFS and OS in HCC patients with hepatectomy.

#### The prognostic value of NLR combined with APRI for HCC after hepatectomy

To analyze the prognostic value for HCC survival of combining NLR and APRI, we set up NLR ≤ 2 or APRI ≤ 1.68 as the score of 0 and NLR > 2 or APRI > 1.68 as the score of 1. After combining NLR with APRI, patients...
Table 1  Prognostic factors for DFS and OS by univariate analysis

| Variables          | n   | DFS 1-yr | 3-ys | 5-ys | P   | OS 1-yr | 3-ys | 5-ys | P   |
|--------------------|-----|----------|------|------|-----|---------|------|------|-----|
| Gender             |     |          |      |      |     |         |      |      |     |
| Male               | 285 | 43.5 %   | 29.8 % | 25.8 % | 0.006 | 69.5 % | 44.6 % | 37.1 % | 0.026 |
| Female             | 36  | 55.6 %   | 38.9 % | 38.9 % |      | 83.3 % | 61.1 % | 55.6 % |      |
| Age (yrs)          |     |          |      |      |     |         |      |      |     |
| < 60               | 244 | 43.9 %   | 32.4 % | 29.5 % | 0.565 | 70.1 % | 47.1 % | 39.7 % | 0.677 |
| ≥ 60               | 77  | 48.1 %   | 26.0 % | 20.3 % |      | 74.0 % | 44.2 % | 37.6 % |      |
| HBsAg              |     |          |      |      |     |         |      |      |     |
| Positive           | 281 | 42.0 %   | 29.5 % | 25.4 % | 0.049 | 69.4 % | 44.8 % | 38.0 % | 0.123 |
| Negative           | 40  | 65.0 %   | 40.0 % | 40.0 % |      | 82.5 % | 57.5 % | 47.5 % |      |
| AFP (μg/L)         |     |          |      |      |     |         |      |      |     |
| < 200              | 139 | 54.0 %   | 36.7 % | 34.5 % | 0.002 | 77.7 % | 51.8 % | 45.3 % | 0.015 |
| ≥ 200              | 182 | 37.9 %   | 26.4 % | 21.8 % |      | 65.9 % | 42.3 % | 34.5 % |      |
| ALT (U/L)          |     |          |      |      |     |         |      |      |     |
| < 80               | 265 | 47.5 %   | 32.4 % | 28.5 % | 0.108 | 73.2 % | 49.8 % | 41.8 % | 0.019 |
| ≥ 80               | 56  | 32.1 %   | 23.2 % | 21.4 % |      | 60.7 % | 30.4 % | 26.8 % |      |
| Hb (g/L)           |     |          |      |      |     |         |      |      |     |
| ≤ 120              | 57  | 33.3 %   | 19.3 % | 17.5 % | 0.068 | 70.2 % | 35.1 % | 29.8 % | 0.215 |
| > 120              | 264 | 47.3 %   | 33.3 % | 29.4 % |      | 71.2 % | 48.9 % | 41.2 % |      |
| WBC (×10^9)        |     |          |      |      |     |         |      |      |     |
| < 10               | 287 | 46.0 %   | 31.7 % | 27.8 % | 0.384 | 72.1 % | 46.3 % | 39.6 % | 0.795 |
| ≥ 10               | 34  | 35.3 %   | 23.5 % | 23.5 % |      | 61.8 % | 47.1 % | 35.3 % |      |
| Lymphocyte (×10^9) |     |          |      |      |     |         |      |      |     |
| < 4                | 313 | 44.7 %   | 30.7 % | 27.0 % | 0.475 | 71.2 % | 46.3 % | 39.2 % | 0.988 |
| ≥ 4                | 8   | 50.0 %   | 37.5 % | 37.5 % |      | 62.5 % | 50.0 % | 37.5 % |      |
| TNM                |     |          |      |      |     |         |      |      |     |
| I                  | 184 | 60.9 %   | 42.9 % | 39.1 % | <0.001 | 84.8 % | 61.4 % | 55.4 % | <0.001 |
| II-III             | 137 | 23.4 %   | 14.6 % | 11.3 % |      | 52.6 % | 26.3 % | 17.4 % |      |
| Cirrhosis          |     |          |      |      |     |         |      |      |     |
| No                 | 68  | 41.2 %   | 27.9 % | 25.0 % | 0.541 | 76.5 % | 47.1 % | 38.2 % | 0.745 |
| Yes                | 253 | 45.8 %   | 31.6 % | 27.9 % |      | 69.6 % | 46.2 % | 39.5 % |      |
| PVTT               |     |          |      |      |     |         |      |      |     |
| No                 | 263 | 52.5 %   | 35.7 % | 31.8 % | <0.001 | 79.5 % | 52.9 % | 45.6 % | <0.001 |
| Yes                | 58  | 10.3 %   | 8.6 %  | 6.9 %  |      | 32.8 % | 17.2 % | 10.1 % |      |
| Tumor number       |     |          |      |      |     |         |      |      |     |
| single             | 226 | 54.0 %   | 38.5 % | 34.0 % | <0.001 | 77.0 % | 54.9 % | 48.6 % | <0.001 |
| multiple           | 95  | 23.2 %   | 12.5 % | 11.0 % |      | 56.8 % | 26.3 % | 16.7 % |      |
| Tumor size (cm)    |     |          |      |      |     |         |      |      |     |
| < 5                | 111 | 69.4 %   | 51.4 % | 43.9 % | <0.001 | 88.4 % | 68.7 % | 60.7 % | <0.001 |
| ≥ 5                | 210 | 31.9 %   | 20.0 % | 18.5 % |      | 61.4 % | 34.3 % | 27.5 % |      |
| Complication       |     |          |      |      |     |         |      |      |     |
| No                 | 273 | 44.7 %   | 32.6 % | 28.4 % | 0.356 | 72.2 % | 46.9 % | 40.6 % | 0.345 |
| Yes                | 48  | 45.8 %   | 20.8 % | 20.8 % |      | 64.6 % | 43.8 % | 31.0 % |      |
| Tumor differentiation |   |          |      |      |     |         |      |      |     |
were allocated into three groups. Patients with both NLR ≤ 2 and APRI ≤ 1.68 were calculated to have a score of 0, and were recruited into group 1. Patients with NLR > 2 and APRI ≤ 1.68 or with NLR ≤ 2 and APRI > 1.68 were in Group 2, with the total score of 1. Finally, those with both NLR > 2 and APRI > 1.68 were in Group 3 with the total score of 2 (Table 4). Patients in Group 1 had the best DFS and OS rates, followed by those in Group 2; patients in Group 3 had the worst prognosis.

**Table 1** Prognostic factors for DFS and OS by univariate analysis (Continued)

| Variables            | DFS HR | 95%CI  | P   | OS HR | 95%CI  | P   |
|----------------------|--------|--------|-----|-------|--------|-----|
| NLR                  |        |        |     |       |        |     |
| ≤ 2                  |        |        |     |       |        |     |
| > 2                  |        |        |     |       |        |     |
| PLR                  |        |        |     |       |        |     |
| ≤ 115                |        |        |     |       |        |     |
| > 115                |        |        |     |       |        |     |
| APRI                 |        |        |     |       |        |     |
| ≤ 1.68               |        |        |     |       |        |     |
| > 1.68               |        |        |     |       |        |     |
| PNI                  |        |        |     |       |        |     |
| ≤ 45                 |        |        |     |       |        |     |
| > 45                 |        |        |     |       |        |     |

**TNM** Tumor Node Metastasis, **AFP** Alpha-fetoprotein, **HBsAg** hepatitis B surface antigen, **PLT** platelet, **PVTT** portal vein tumor thrombi, **NLR** neutrophil/lymphocyte ratio, **PLR** platelet/lymphocyte ratio, **PNI** prognostic nutritional index, **APRI** Aspartate aminotransferase /platelet count ratio index

**Table 2** Independent prognostic factors for DFS and OS by the multivariate Cox proportional hazards regression model

| Variables | DFS HR | 95%CI   | P  | OS HR | 95%CI   | P  |
|-----------|--------|---------|----|-------|---------|----|
| NLR       | 1.405  | 1.039-1.907 | 0.027 |       |         |    |
| APRI      | 1.449  | 1.083-1.939 | 0.014 |       |         |    |
| PLT       | 1.405  | 1.076-1.833 | 0.012 |       |         |    |
| PVTT      | 1.732  | 1.185-2.531 | 0.005 |       |         |    |
| TNM       | 1.981  | 1.469-2.672 | <0.001 |       |         |    |
| AFP       | 1.317  | 1.006-1.724 | 0.045 |       |         |    |

**HR** hazard ratio, **CI** confidence interval, **TNM** Tumor Node Metastasis, **AFP** Alpha-fetoprotein, **PVTT** portal vein tumor thrombi, **NLR** neutrophil/lymphocyte ratio, **PLT** platelet/lymphocyte ratio, **PNI** prognostic nutritional index, **APRI** Aspartate aminotransferase (AST)/platelet count ratio index

![ROC Curve](image)
| Variables                        | Cases | NLR      | P value | APRI      | $P$ value |
|---------------------------------|-------|----------|---------|-----------|-----------|
|                                |       | ≤2       | >2      | ≤1.68     | >1.68     |
| **Age(yrs)**                   |       |          |         |           |           |
| ≥ 60                            | 77    | 32(41.6%) | 45(58.4%) | 0.219     | 24(31.2%) | 53(68.8%) | 0.598   |
| < 60                            | 244   | 121(49.6%) | 123(50.4%) |           |           |
| **Gender**                     |       |          |         |           |           |
| Male                            | 285   | 135(47.4%) | 150(52.6%) | 0.766     | 92(32.3%) | 193(67.7%) | 0.146   |
| Female                          | 36    | 18(50.0%)  | 18(50.0%) | 16(44.4%) | 20(55.6%) |
| **HCC family history**         |       |          |         |           |           |
| Yes                             | 24    | 8(33.3%)  | 16(66.7%) | 0.144     | 8(33.3%)  | 16(66.7%) | 0.973   |
| No                              | 297   | 145(48.8%) | 152(51.2%) | 100(33.7%) | 197(66.3%) |
| **HBsAg**                      |       |          |         |           |           |
| Positive                        | 281   | 134(47.7%) | 147(52.3%) | 0.982     | 86(30.6%) | 195(69.4%) | 0.002   |
| Negative                        | 40    | 19(47.5%)  | 21(52.5%) | 22(55.0%) | 18(45.0%) |
| **ALT(U/L)**                   |       |          |         |           |           |
| < 80                            | 265   | 126(47.5%) | 139(52.5%) | 0.928     | 104(39.2%) | 161(60.8%) | <0.001  |
| ≥ 80                            | 56    | 27(48.2%)  | 29(51.8%) | 47(7.1%)   | 52(92.9%) |
| **TBIL(μmol/L)**               |       |          |         |           |           |
| < 34.2                          | 294   | 144(49.0%) | 150(51.0%) | 0.119     | 106(36.1%) | 188(63.9%) | 0.003   |
| ≥ 34.2                          | 27    | 9(33.3%)   | 18(66.7%) | 27(7.4%)   | 25(92.6%) |
| **PLT(×10⁹)**                  |       |          |         |           |           |
| ≥ 100                           | 292   | 136(46.6%) | 150(53.4%) | 0.215     | 108(37.0%) | 184(63.0%) | <0.001  |
| < 100                           | 29    | 17(58.6%)  | 12(41.4%) | 0(0.0%)    | 29(100.0%) |
| **Cirrhosis**                  |       |          |         |           |           |
| Yes                             | 253   | 126(49.8%) | 127(50.2%) | 0.139     | 74(29.2%)  | 179(70.8%) | 0.001   |
| No                              | 68    | 27(39.7%)  | 41(60.3%) | 34(50.0%)  | 34(50.0%) |
| **AFP(μg/L)**                  |       |          |         |           |           |
| ≥ 200                           | 182   | 76(41.8%)  | 106(58.2%) | 0.015     | 57(31.3%)  | 125(68.7%) | 0.313   |
| < 200                           | 139   | 77(55.4%)  | 62(44.6%) | 51(36.7%)  | 88(63.3%) |
| **Tumor size(cm)**             |       |          |         |           |           |
| > 5                             | 210   | 76(36.2%)  | 134(63.8%) | <0.001    | 65(31.0%)  | 145(69.0%) | 0.160   |
| ≤ 5                             | 111   | 77(69.4%)  | 34(30.6%) | 43(38.7%)  | 68(61.3%) |
| **Tumor number**               |       |          |         |           |           |
| Single                          | 226   | 112(49.6%) | 114(50.4%) | 0.295     | 80(35.4%)  | 146(64.6%) | 0.305   |
| Multiple                        | 95    | 41(43.2%)  | 54(56.8%) | 28(29.5%)  | 67(70.5%) |
| **TNM**                        |       |          |         |           |           |
| I                               | 184   | 96(52.2%)  | 88(47.8%) | 0.061     | 70(38.0%)  | 114(62.0%) | 0.053   |
| II-III                          | 137   | 57(41.6%)  | 80(58.4%) | 38(27.7%)  | 99(72.3%) |
| **Differentiation**            |       |          |         |           |           |
| I-II                            | 248   | 119(48.0%) | 129(52.0%) | 0.832     | 85(34.3%)  | 163(65.7%) | 0.660   |
| III-IV                          | 73    | 34(46.6%)  | 39(53.4%) | 23(31.5%)  | 50(68.5%) |
| **PVTT**                       |       |          |         |           |           |
| Yes                             | 58    | 20(34.5%)  | 38(65.5%) | 0.026     | 7(12.1%)   | 51(87.9%)  | <0.001  |
| No                              | 263   | 133(50.6%) | 130(49.4%) | 101(38.4%) | 162(61.6%) |
respectively, \( P = 0.001 \) and Group 3 (31.6 %, 21.1 % and 19.2 %, respectively, \( P < 0.001 \)). Similarly, the 1-, 3- and 5-year OS rates of Group 1 (87.3 %, 69.1 % and 65.5 %, respectively) were also significantly higher than those of Group 2 (76.3 %, 51.3 % and 39.3 %, respectively, \( P = 0.002 \)) and Group 3 (56.1 %, 28.9 % and 26.3 %, respectively, \( P < 0.001 \)) (Fig. 4a and b). Furthermore, we found that the 1-, 3- and 5-year DFS and OS rates of Group 2 were both significantly higher than those of Group 3 \( (P = 0.013 \text{ and } P = 0.002) \).

**Discussion**

Surgical resection is the mainstay of curative therapy for HCC. However, it is well understood that malnutrition is of particular concern in patients with HCC due to the concomitant underlying fibrosis and cirrhosis [17]. In addition, hepatectomy can cause a series of postoperative changes in the metabolic, endocrine, neuroendocrine and immune systems, which can impair immunological functions and contribute to an increased risk of postoperative complications and metastasis in HCC patients after surgery. Theoretically, malnutrition, immunological status, fibrosis and cirrhosis may act as predictors of survival in HCC patients after curative resection.

Increasing evidence seems to indicate that the host inflammatory response is correlated with the occurrence and development of HCC, so that it can serve to predict the clinical outcomes of patients with HCC. Several studies have shown that an elevated NLR is associated with poor prognosis in patients with HCC undergoing surgical resection [18], transplantation [19], transarterial chemoembolisation [20] and radiofrequency ablation [9]. PNI was first reported by Onodera et al. in Japan for the assessment of the immunologic and nutritional status of patients [21]. Pinato et al. [5] first demonstrated that PNI was useful for assessing prognosis in patients with HCC. Chan et al. [8] indicated that PNI was a significant

**Table 3** Correlation between preoperative NLR, APRI and clinico-pathologic characteristics in HCC (Continued)

|        | NLR ≤ 2 | NLR > 2 | APRI ≤ 1.5 | APRI > 1.5 |
|--------|---------|---------|------------|------------|
| Yes    | 235     | 101(43.0 %) | 134(57.0 %) | 0.005      | 67(28.5 %) | 168(71.5 %) | 0.001 |
| No     | 86      | 52(60.5 %)  | 34(39.5 %)  |            | 41(47.7 %) | 45(52.3 %)  |      |

**Fig. 2** Relationship between NLR and DFS/OS of HCC patients after hepatectomy. **a** DFS of patients with NLR > 2 was significantly shorter than those with NLR ≤ 2 \( (P < 0.001, \text{log-rank test}) \). **b** OS of patients with NLR > 2 was also markedly shorter than those with NLR ≤ 2 \( (P < 0.001, \text{log-rank test}) \).
prognostic factor for OS and DFS of patients with very early/early stage HCC receiving curative surgery. Oka-
mura and colleagues [22] further pointed out that NLR
and PNI were predictors of overall survival in patients
who had undergone hepatectomy for HCC with curative
intent. PLR is proposed to be a predictor of thrombotic
and inflammatory conditions, thus making it an attract-
vie inflammation-related biomarker for tumors also. For
HCC, Xue et al. [23] indicated that a high baseline PLR
is a useful predictor of poor survival in patients under-
going chemoembolization. Xia et al. [24] also found that
a high level of pre-transplant PLR was associated with
advanced tumor stage and aggressive tumor behavior,
making it a useful indicator for post-transplant HCC
recurrence.

In our study, we compared the prognostic value of
various inflammation markers, based on prognostic
scores for NLR, PLR and PNI. We found that
preoperative NLR, PLR and PNI were all significant
prognostic factors for DFS and OS in patients with
HCC. High levels of NLR (>2), high levels of PLR (>115)
and low levels of PNI (≤45) predicted poor prognosis in
HCC patients with curative resection. However, NLR
was superior in this aspect to PLR and PNI; what is
more, NLR was the only independent predictive factor
for both DFS and OS in HCC patients. In addition, PLR
was the only independent predictive factor for OS in
HCC patients. We also found a significant correlation
between NLR and several clinico-pathological character-
istics: AFP, PVTT, tumor size, tumor encapsulation, re-
currence, PNI and PLR.

A three-step process of hepatitis → liver fibrosis/
cirrhosis → HCC is believed to be the primary mech-
anism of hepatocarcinogenesis. Wu and colleagues
[25] reported that high viral loads and hepatic inflam-
matory activity were associated with late HCC recur-
rence and that tumor factors were associated with
early HCC recurrence. Hung et al. [26] found that
the degree of liver fibrosis is associated with tumor
recurrence as well as with overall survival in small
and solitary HBV-related HCC patients with surgical
resection. Although liver biopsy is the gold standard
for the assessment of liver fibrosis, it is a high-risk
procedure and usually complicated by pain, bleeding,
hemothorax, bile duct injury or risk of penetration of
the abdominal viscera. In addition, sampling errors
and inter-observer variation decrease the reliability of
liver biopsy as a predictive tool. Recently, APRI was
validated as a simple, feasible, noninvasive way to as-
sess the degree of liver fibrosis in patients with
chronic hepatitis B or C [27, 28]. APRI was also
found to be a prognostic biomarker in small HCC

Table 4 A novel and accurate predictor for HCC: the
combination of NLR and APRI

| Variable | Score |
|----------|-------|
| NLR      |       |
| ≤ 2      | 0     |
| > 2      | 1     |
| APRI     |       |
| ≤ 1.68   | 0     |
| > 1.68   | 1     |
| Prognostic stratification | |
| 0        | Low risk of mortality |
| 1        | Intermediate risk of mortality |
| 2        | High risk of mortality |

Fig. 3 Relationship between APRI and DFS/OS of HCC patients after hepatectomy. a DFS of patients with APRI > 1.68 was significantly shorter than those with APRI ≤ 1.68 (P < 0.001, log-rank test). b OS of patients with APRI > 1.68 was also markedly shorter than those with APRI ≤ 1.68 (P < 0.001, log-rank test)
patients after radiofrequency ablation therapy and surgical resection [14, 29]. APRI was also found useful in predicting HCC risk in patients with non alcoholic fatty liver disease [30] or HBV.

Our results showed that APRI was superior to PLR or PNI as an independent predictor of both DFS and OS in HCC patients with hepatectomy. APRI > 1.68 predicted a short DFS and OS in HCC patients. In correlation analysis, we found that, as in previous studies [27, 28], APRI was intimately associated with cirrhosis and HBV status. High APRI levels predicted the condition of cirrhosis and HBV infection. In addition, high APRI levels were positively correlated to PVTT, incomplete tumor encapsulation and tumor relapse, and negatively correlated to PNI.

As mentioned above, the non-tumor factors, including inflammatory condition, immune state, viral infection and liver fibrosis, play an important role in determining tumor recurrence in HCC patients. Accordingly, NLR and APRI were both independent predictors of both DFS and OS in HCC patients. Given that NLR is an accurate inflammatory marker, and APRI can assess the degree of liver fibrosis, we hypothesize that the combination of NLR and APRI reflects the range of non-tumor factors, thereby enabling more precise prediction of outcomes in HCC patients with curative resection.

Excitingly, our results showed that the combination of NLR and APRI has a better prognostic value than either one alone. For example, the data showed that patients in Group 1 (both NLR ≤ 2 and APRI ≤ 1.68) had the best DFS and OS rates, with 1-, 3- and 5-year DFS rates of 65.5 %, 52.7 % and 50.9 %, respectively, and 1-, 3- and 5-year OS rates of 87.3 %, 69.1 % and 65.5 %, respectively. However, the prognosis was worst in patients in Group 3 (both NLR > 2 and APRI > 1.68), whose 1-, 3- and 5-year DFS rates were only 31.6 %, 21.1 % and 19.2 %, respectively, and whose 1-, 3- and 5-year OS rates were only 56.1 %, 28.9 % and 26.3 %, respectively. The outcomes for patients in Group 2 (both NLR > 2 and APRI ≤ 1.68, or both NLR ≤ 2 and APRI > 1.68), fell between those of the above two groups, with 1-, 3- and 5-year DFS rates of 47.4 %, 30.3 % and 24.7 %, respectively, and 1-, 3- and 5-year OS rates of 76.3 %, 51.3 % and 39.3 %, respectively. Furthermore, the difference between any two groups was significant. So the combination of NLR and APRI inevitably possesses both accurate and clinically meaningful prognostic value for HCC patients with curative resection, for example, both NLR > 2 and APRI > 1.68 represents high risk of mortality, both NLR ≤ 2 and APRI ≤ 1.68 represents low risk of mortality, and the other represents intermediate risk of mortality. It is very easy and valuable to accurately predict the prognosis of HCC patients in clinical. Its mechanisms may be that the combination of NLR and APRI reflects most of non-tumor factors, including inflammatory condition, immune state, viral infection and liver fibrosis, rather than a certain aspect of non-tumor factors. So we can speculate that the combination of NLR and APRI is useful to guide the follow-up and further treatment of HCC patients after curative resection. For example, we should follow up closely so as to find the early tumor recurrence for the patients with both NLR > 2 and APRI > 1.68. It may be better to follow up once a month for this kind of patients. Even we can give some initiative treatments to these patients, such as TACE, systemic chemotherapy, or cellular immunotherapy, etc.

Certainly, the present study has some limitations. First, it is a retrospective, single-institution study with a relatively small number of patients. A well-designed,
prospective study with a larger number of patients with HCC who underwent radical surgery is needed. Second, we were not able to split our data set into a training data set and a test data set for statistical validation because of the small number of patients. So it is worthwhile to conduct additional studies to validate our findings and test their clinical applicability in HCC treatment in the future.

**Conclusions**

In summary, our study determined that NLR and APRI were superior to PNI and PLR, and were independent predictors of the prognosis for HCC patients with curative resection. Their high levels predicted poor outcomes in HCC patients: early recurrence and short lifetime. Excitingly, NLR combined with APRI was more sensitive than either scale alone in predicting DFS and OS in patients with HCC. The combination of NLR and APRI may be a useful prognostic tool to determine survival in patients with HCC after resection, and to further guide their follow-up and postoperative treatment.

**Abbreviations**

AFP: alpha-fetoprotein; ALT: alanine aminotransferase; APRI: aspartate aminotransferase/platelet count ratio index; AST: aspartate aminotransferase; CT: computed tomography; DFS: disease-free survival; HBsAg: hepatitis B surface antigen; HBV: Hepatitis B; HCC: hepatocellular cancer; MRI: Magnetic resonance imaging; NLR: neutrophil/lymphocyte ratio; OS: overall survival; PLR: platelet/lymphocyte ratio; PNI: prognostic nutritional index; PVT: portal vein tumor thrombus; ROC: receiver operating characteristics; TACE: transarterial arterial chemoembolization; TBL: total billirubin.; TNM: Tumor Node Metastasis.

**Competing interests**

The authors declare that they have no competing interests.

**Authors’ contributions**

FJ, YL, SJF and YPH were the main authors of the manuscript. They were involved in the conception, design and coordination of the study as well as in data analysis, interpretation of results and drafting the manuscript. YPH was in charge of all experimental procedures. ZYG, MS, SLS, SQL, BGP and FJ, YL, SJF and YPH were the main authors of the manuscript. They were involved in the conception, design and coordination of the study as well as in data analysis, interpretation of results and drafting the manuscript. All authors contributed to the interpretation of data and critically revised the manuscript. All authors read and approved the final manuscript.

**Acknowledgments**

This study was supported by grants from the National Natural Science Foundation of China (No. 81202198), the Science and Technology Project of Guangdong Province (No. 2012b031800099), the Doctoral Fellowship of Higher Education of China (No. 200805581172), the Guangdong Provincial Key Laboratory Construction on Organ Donation and Transplant Immunology (No. 2013A061401007), the Scientific Research Foundation for Returned Overseas Chinese Scholars and the State Education Ministry (No. 311, in 2015).
22. Okamura Y, Ashida R, Ito T, Sugiuara T, Mori K, Uesaka K. Preoperative neutrophil to lymphocyte ratio and prognostic nutritional index predict overall survival after hepatectomy for hepatocellular carcinoma. World J Surg. 2015;39(6):1501–9.

23. Xue TC, Jia QA, Ge NL, Zhang BH, Wang YH, Ren ZG, Ye SL. The platelet-to-lymphocyte ratio predicts poor survival in patients with huge hepatocellular carcinoma that received transarterial chemoembolization. Tumor Biol. 2015;36(8):6045–51

24. Xia W, Ke Q, Wang Y, Wang W, Zhang M, Shen Y, et al. Predictive value of pre-transplant platelet to lymphocyte ratio for hepatocellular carcinoma recurrence after liver transplantation. World J Surg Oncol. 2015;13(1):60.

25. Wu J-C, Huang Y-H, Chau G-Y, Su C-W, Lai C-R, Lee P-C, et al. Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma. J Hepatol. 2009;51(5):890–7.

26. Hung H-H, Su C-W, Lai C-R, Chau G-Y, Chan C-C, Huang Y-H, et al. Fibrosis and AST to platelet ratio index predict post-operative prognosis for solitary small hepatitis B-related hepatocellular carcinoma. Hepatol Int. 2010;4(4):691–9.

27. Ma J, Jiang Y, Gong G. Evaluation of seven noninvasive models in staging liver fibrosis in patients with chronic hepatitis B virus infection. Eur J Gastroenterol Hepatol. 2013;25(4):428–34.

28. Boursier J, Brochard C, Bertrais S, Michalak S, Gallois Y, Fouchard-Hubert I, et al. Combination of blood tests for significant fibrosis and cirrhosis improves the assessment of liver-prognosis in chronic hepatitis C. Aliment Pharmacol Ther. 2014;40(2):178–88.

29. Kao W-Y, Chou Y-Y, Hung H-H, Chou Y-H, Su C-W, Wu J-C, et al. Risk factors for long-term prognosis in hepatocellular carcinoma after radiofrequency ablation therapy: the clinical implication of aspartate aminotransferase–platelet ratio index. Eur J Gastroenterol Hepatol. 2011;23(6):528–36.

30. Kawamura Y, Atase Y, Ikeda K, Seko Y, Imai N, Hosaka T, et al. Large-scale long-term follow-up study of Japanese patients with non-alcoholic fatty liver disease for the onset of hepatocellular carcinoma. Am J Gastroenterol. 2012;107(2):253–61.

Submit your next manuscript to BioMed Central and we will help you at every step:

- We accept pre-submission inquiries
- Our selector tool helps you to find the most relevant journal
- We provide round the clock customer support
- Convenient online submission
- Thorough peer review
- Inclusion in PubMed and all major indexing services
- Maximum visibility for your research

Submit your manuscript at www.biomedcentral.com/submit